Envoy Medical Inc. has approved new stock option awards for its Chief Executive Officer, Brent Lucas, and Interim Chief Financial Officer, Robert Potashnick. Under the company's 2023 Equity Incentive Plan, Mr. Lucas received options to purchase 200,000 shares of Class A Common Stock, while Mr. Potashnick received options for 15,000 shares. The options carry an exercise price of $0.53 per share, reflecting the closing price on February 5, 2026. Vesting terms stipulate that 25% of the options vest after one year, with the remaining options vesting pro rata over the following 36 months. The options will expire 10 years from the award date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-014878), on February 11, 2026, and is solely responsible for the information contained therein.